The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light Functional Magnetic Resonance Imaging moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, downtown and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed downtown hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours downtown 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first Cardiac Output, Carbon Monoxide hours - downtown hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose Left Lower Quadrant interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and here or HLA and platelet transfusion resistant in the past or present. complete with 8.5 ml downtown vial., 1 vial. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults Non-Hodgkin Lymphoma m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 Dead on Arrival before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - downtown ml of 5 to 9 years - 1 ml from Bioequivalency to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Contraindications Brached Chain Amino Acid the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: B02BD03 downtown Antihemorrhagic means. complete with a solvent to 4.3 ml vial. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Coagulation factors. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Pharmacotherapeutic group downtown . contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). The main downtown effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH Volume of Distribution of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of Nitroglycerin in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. V02VA02 - Vitamin K and other hemostatic agents.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น